Cargando…

Fasiglifam (TAK‐875) has dual potentiating mechanisms via Gαq‐GPR40/FFAR1 signaling branches on glucose‐dependent insulin secretion

Fasiglifam (TAK‐875) is a free fatty acid receptor 1 (FFAR1)/G‐protein–coupled receptor 40 (GPR40) agonist that improves glycemic control in type 2 diabetes with minimum risk of hypoglycemia. Fasiglifam potentiates glucose‐stimulated insulin secretion (GSIS) from pancreatic β‐cells glucose dependent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakuma, Kensuke, Yabuki, Chiori, Maruyama, Minoru, Abiru, Akiko, Komatsu, Hidetoshi, Negoro, Nobuyuki, Tsujihata, Yoshiyuki, Takeuchi, Koji, Habata, Yugo, Mori, Masaaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876146/ https://www.ncbi.nlm.nih.gov/pubmed/27433346 http://dx.doi.org/10.1002/prp2.237

Ejemplares similares

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
por: Yabuki, Chiori, et al.
Publicado: (2013)

Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner
por: Kim, MinJeong, et al.
Publicado: (2018)

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury
por: Wolenski, Francis S., et al.
Publicado: (2017)

Temporal and Spatial Transcriptional Fingerprints by Antipsychotic or Propsychotic Drugs in Mouse Brain
por: Sakuma, Kensuke, et al.
Publicado: (2015)

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
por: Naik, H, et al.
Publicado: (2013)

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial
por: Kaku, K, et al.
Publicado: (2015)

Anatomical Transcriptome of G Protein-Coupled Receptors Leads to the Identification of a Novel Therapeutic Candidate GPR52 for Psychiatric Disorders
por: Komatsu, Hidetoshi, et al.
Publicado: (2014)

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes
por: Kaku, Kohei, et al.
Publicado: (2013)

Potential Utility of Biased GPCR Signaling for Treatment of Psychiatric Disorders
por: Komatsu, Hidetoshi, et al.
Publicado: (2019)

Dysfunctional GPR40/FFAR1 signaling exacerbates pain behavior in mice
por: Nakamoto, Kazuo, et al.
Publicado: (2017)

EPA Prevents the Development of Abdominal Aortic Aneurysms through Gpr-120/Ffar-4
por: Kamata, Ryo, et al.
Publicado: (2016)

Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
por: Lückmann, Michael, et al.
Publicado: (2019)

A high molar activity (18)F-labeled TAK-875 derivative for PET imaging of pancreatic β-cells
por: Dornan, Mark H., et al.
Publicado: (2018)

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
por: Bazydlo-Guzenda, Katarzyna, et al.
Publicado: (2021)

Autocrine negative feedback regulation of lipolysis through sensing of NEFAs by FFAR4/GPR120 in WAT
por: Husted, Anna Sofie, et al.
Publicado: (2020)

The molecular mechanism of phytosphingosine binding to FFAR4/GPR120 differs from that of other fatty acids
por: Nagasawa, Tomotaka, et al.
Publicado: (2021)

GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery
por: Carullo, Gabriele, et al.
Publicado: (2021)

Expression of FFAR3 and FFAR4 Is Increased in Gastroesophageal Reflux Disease
por: Fabisiak, Adam, et al.
Publicado: (2020)

TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway
por: Chen, Xide, et al.
Publicado: (2019)

Polymorphisms in FFAR4 (GPR120) Gene Modulate Insulin Levels and Sensitivity after Fish Oil Supplementation
por: Vallée Marcotte, Bastien, et al.
Publicado: (2017)

Lack of FFAR1/GPR40 Does Not Protect Mice From High-Fat Diet–Induced Metabolic Disease
por: Lan, Hong, et al.
Publicado: (2008)

Cloning, Identification and Functional Characterization of Bovine Free Fatty Acid Receptor-1 (FFAR1/GPR40) in Neutrophils
por: Manosalva, Carolina, et al.
Publicado: (2015)

FFAR4 (GPR120) Signaling Is Not Required for Anti-Inflammatory and Insulin-Sensitizing Effects of Omega-3 Fatty Acids
por: Pærregaard, Simone Isling, et al.
Publicado: (2016)

FFAR1/GPR40 Contributes to the Regulation of Striatal Monoamine Releases and Facilitation of Cocaine-Induced Locomotor Activity in Mice
por: Sadamura, Yuko, et al.
Publicado: (2021)

GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve
por: Ueno, Hikaru, et al.
Publicado: (2019)

Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury
por: Longo, Diane M, et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
por: Marcinak, John, et al.
Publicado: (2018)

FFAR2-FFAR3 receptor heteromerization modulates short-chain fatty acid sensing
por: Ang, Zhiwei, et al.
Publicado: (2018)

Molecular characterization of free fatty acid receptors FFAR2 and FFAR3 in the domestic cat
por: Yamamoto, Ichiro, et al.
Publicado: (2020)

GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans
por: Stone, Virginia M., et al.
Publicado: (2014)

GPR40 (FFAR1) – Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo
por: Hauge, Maria, et al.
Publicado: (2014)

Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine
por: Christensen, Louise W, et al.
Publicado: (2015)

An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis
por: Sivaprakasam, S, et al.
Publicado: (2016)

PT640. The dysfunction of brain free fatty acid receptor GPR40/FFAR1 signaling relate to the development of chronic pain
por: Nakamoto, Kazuo, et al.
Publicado: (2016)

PS04. The changes of emotional behavior in a free fatty acid receptor 1, GPR40/FFAR1, deficient mice
por: Aizawa, Fuka, et al.
Publicado: (2016)

Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action
por: Lückmann, Michael, et al.
Publicado: (2022)

Decoy bypass for appetite suppression in obese adults: role of synergistic nutrient sensing receptors GPR84 and FFAR4 on colonic endocrine cells
por: Peiris, Madusha, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function
por: Mayer, Michael, et al.
Publicado: (2014)

Antihypertrophic Effects of Small Molecules that Maintain Mitochondrial ATP Levels Under Hypoxia
por: Nagai, Hiroaki, et al.
Publicado: (2017)

FFAR2 antagonizes TLR2- and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-κB
por: Kim, Mi-Jeong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4uice8bfj64cjdgh0a2501koht